The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
The board of Cyxone AB (publ), corporate no. 559020-5471, ("Cyxone" or the "Company") has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders for a total of approximately SEK 23 million before deductions for transaction costs (the "Rights Issue"). The decision has been made with the support of authorization from the annual general meeting in 2024. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa